It is noteworthy that high NAT1 expression was reported to have a role in ER+ female BC as a predictive marker of response to tamoxifen [32], which is the most often used first antiestrogen drug in MBC patients eligible for endocrine therapy [33]. The gene discussed is NAT1; the disease is breast cancer.